Remote Monitoring for Acute Care at Home: Evidence from an Independent Clinical Trial

Findings from the landmark iCAD clinical trial, and what they mean for virtual care at scale

In June 2026, a landmark randomised clinical trial published in the ANZ Journal of Surgery demonstrated something that challenges a fundamental assumption of acute surgical care. Evidence suggests that for patients with acute uncomplicated diverticulitis, home is as safe as hospital — and patients prefer it. Ninety-three percent of patients managed through the iCAD virtual care pathway completed treatment without crossing over to inpatient care. There were zero major complications across both trial phases. The trial was underpinned by Miya Precision, the platform used by Sydney Virtual Hospital to deliver virtual care to more than 85,000 patients since 2020. 

Yang et al., ANZ Journal of Surgery, June 2026. doi: 10.1111/ans.70826 

• 93%
  Treatment retention across both trial phases 
• 00
  Major Complications (Clavien-Dindo grade ≥3)
• 88%
  Rated care ‘excellent’ vs 40% inpatient (p=0.03)
• 88%
  Healthcare needs ‘always met’ vs 47% inpatient (p=0.02)

1. The Problem This Trial Was Designed to Solve

Acute uncomplicated diverticulitis is one of the most common reasons for acute surgical admission in Australia and globally. In 2022–2023, there were 19,142 hospital admissions for uncomplicated diverticulitis in Australia alone, with an average length of stay of 2.9 days — up from 13,600 admissions a decade earlier. The condition is conventionally managed with IV antibiotics, bowel rest, and analgesia in a hospital bed.

The clinical evidence, however, has been pointing in a different direction for some time. The DIVER trial and the DINAMO study both demonstrated that selected patients with uncomplicated diverticulitis can be safely managed as outpatients. Yet most Australian colorectal surgeons continue to admit patients — a 2017 survey found 76% preferred hospital admission, and only 4% would provide outpatient care without antibiotics.

The reason is not only clinical scepticism. It is the absence of a safe and governable alternative. Clinicians are willing to consider out-of-hospital management, but not without the ability to monitor patients remotely, identify deterioration early and respond when needed. The iCAD trial was designed to provide exactly that infrastructure — and to test whether it worked. 

“Concerns that early patient deterioration may be missed lead to most Australian colorectal surgeons admitting patients for at least a short period of observation.” — Yang et al., 2026

2. The iCAD Trial: Design and Results 

Study Design

The Virtual Care of Acute Diverticulitis (iCAD) trial was a prospective, multicentre, Phase I/II randomised clinical trial conducted across Sydney Local Health District, New South Wales, Australia. Phase I enrolled 10 patients directly into the iCAD pathway at RPA Virtual Hospital, (now known as Sydney Virtual Hospital). Phase II randomised 40 patients across three hospitals — Royal Prince Alfred, Concord Repatriation General, and Canterbury Hospital — in a 1:1 ratio to either virtual care or conventional inpatient care. 

Patients were eligible if they were aged 18 or over and presented to a Sydney Local Health District (SLHD) emergency department with acute uncomplicated diverticulitis confirmed by CT. The trial was prospectively registered with the Australia New Zealand Clinical Trials Registry and received ethics approval from the SLHD Human Research Ethics Committee.  

The iCAD Model: Miya Care, iHealth Labs and the Miya Precision Platform

Participants in the virtual care group received an initial dose of intravenous antibiotics in the emergency department, then were discharged home with an iCAD pack containing wearable monitoring devices provided by iHealth Labs and the Miya Care mobile application. The first two days involved a hybrid model — one daily in-person visit from a community nurse for IV antibiotics and clinical assessment, complemented by virtual clinical review. From day three, care was delivered entirely remotely, with the virtual hospital team available 24 hours a day, seven days a week via videoconference. 

The entire model was underpinned by Alcidion’s Miya Precision platform— integrating with the hospital Electronic Medical Record system (EMR), receiving data from wearable devices (pulse oximeter, blood pressure monitor, thermometer) via the Miya Care application and displaying real-time vital signs on a clinical dashboard accessible to the virtual hospital team. The platform also contained the data logic, rules and workflows governing the iCAD programme, including automated patient questionnaires, task management and escalation protocols. 

Patients used the Miya Care application to complete daily questionnaires regarding their progress, complete periodic vital sign observations and take videoconferencing calls with their clinical team. Vital signs were taken using iHealth Labs-provided pulse oximeters, blood pressure monitors and thermometers. Patients were supported in using these devices by a digital health navigator.  

Results: Retention, Clinical Indicators and Patient Satisfaction

  

Outcome	Result
Virtual Treatment retention (Phase I)	100% — no withdrawals, crossovers or major complications
Virtual Treatment retention (Phase II)	89% — 2 of 19 crossed over for clinical reasons
Overall treatment retention	93% — meeting the predefined feasibility threshold of ≥90%
Major complications (Clavien-Dindo ≥3)	Zero across both trial phases
30-day unplanned readmission	5% in iCAD group (1 patient, recurrent diverticulitis)
Rated care ‘excellent’	88% iCAD vs 40% conventional inpatient (p=0.03)
Healthcare needs ‘always met’	88% iCAD vs 47% conventional inpatient (p=0.02)
Consistently informed about care plan	77% iCAD vs 27% conventional inpatient (p=0.02)
Would ‘definitely’ use virtual care again	88% of iCAD participants
Mortality at 60 days	Zero in both groups

“Within our health district, the success of this trial substantially reduced clinical equipoise and the iCAD model of care has subsequently been implemented as standard practice.” — Yang et al., 2026

3. What Made It Work: The Role of Clinical Infrastructure

The iCAD model was clinician-led from start to finish — surgical teams assessed every patient for eligibility, consultant surgeons approved each inclusion and patients were willing to be involved and try a new method of care. But strong clinical teams and governance, as well as patients willing to support innovation exist in health systems everywhere, and virtual care for acute surgical conditions has not become routine practice. Delivering it depends on more than clinical capability and patient consent.  

It would also be easy to attribute the success of the iCAD model to the technology visible to patients — the wearable devices, the video calls, the mobile app. These are undeniably important. But they are the front end of something more impactful.   

A core component of what made the model clinically safe and operationally governable was the infrastructure sitting behind the patient-facing components. Miya Precision connected all elements of the clinical programme into a single coherent system — not a collection of separate tools, but an integrated platform with bidirectional data flows, embedded clinical logic and real-time dashboards. This enabled the small virtual hospital team to safely manage acute surgical patients at home, at scale, 24 hours a day. 

The distinction matters because many virtual care programmes fail not through lack of technology but through lack of integration. Remote monitoring without escalation logic is data without action. Videoconferencing without EMR integration is communication without clinical context. The iCAD trial’s success is underpinned by the platform holding all of these components together and surfacing the right information to the right clinician at the right moment. 

RPA Virtual Hospital (Sydney Virtual Hospital), which provided the governance framework for iCAD, is accredited to the Australian National Safety and Quality Health Service standards. Clinical governance was supported by emergency medicine specialists, general practitioners, visiting medical officers and registered nurses with advanced practice skills. The technology enabled the model. The governance made it safe.

Five conditions the iCAD trial demonstrates are required for safe virtual acute care 

4. The Patient Experience Advantage

The patient-reported outcomes in the iCAD trial are among its most striking findings. The gap in experience ratings — 88% rating care as excellent in the virtual group versus 40% in the conventional inpatient group — is not a marginal finding. It is a statistically significant result (p=0.03) that reflects something structural about what virtual care offers that inpatient care cannot. 

Patients recovering at home are not waiting for a ward round in an unfamiliar environment. They are not subject to the noise, disruption and loss of control that characterise even the best-run hospital wards. They have access to family, control over their immediate environment and regular clinician contact through a model that is less time-pressured and more focused on their specific questions and concerns. 

The iCAD results are consistent with findings from COVID-19 virtual care programmes and the broader Hospital at Home literature. Patients in well-designed virtual models frequently report better experiences than those admitted to hospital — alongside equivalent or better clinical outcomes. This is not an argument against hospitals. It is an argument for using them only when they are genuinely necessary. 

For health system leaders, patient experience data matters beyond satisfaction. It is increasingly linked to regulatory performance, staff retention, reputational standing and in some health systems, funding models. A programme that demonstrably improves patient experience while reducing inpatient bed days is a compelling investment case. 

“88% of iCAD patients said their healthcare needs were always met. 47% of conventional inpatients said the same. The difference is not marginal.“ 

5. Implications for Health Systems Globally

The iCAD trial has implications well beyond diverticulitis. Its significance lies less in the condition it studied, but in what it proves about the model. If virtual care infrastructure can safely manage an acute colorectal surgical condition — one that most Australian surgeons currently admit to hospital as standard practice — the boundaries of what can be governed remotely are considerably wider than many health systems have assumed. 

The trial authors note that future work will broaden inclusion criteria, potentially including select cases of complicated diverticulitis and management without antimicrobial therapy. Within SLHD, the model is already standard practice. The infrastructure is in place. The clinical question is now one of expansion. 

For NHS trusts in England, the relevance is direct. Virtual ward capacity across England exceeded 12,500 beds in 2026, and the NHS 10 Year Health Plan (2025) establishes a clear clinical hierarchy in which care should occur at home if possible. Virtual wards in the NHS Sussex region have already reported as high as 81% admission avoidance rates, demonstrating huge potential to preserve inpatient capacity for those who need it most.    

The challenge for most trusts is not the ambition — it is the infrastructure to make it safe. The iCAD trial demonstrates what that infrastructure looks like in practice. 

For health systems in Australia, New Zealand, Canada and beyond, the question is the same: which conditions currently requiring inpatient admission could be safely managed at home, with appropriate clinical governance and integrated platform support? The answer is almost certainly a longer list than is currently recognised.

Key takeaways for health system leaders 

Virtual care for acute surgical conditions is no longer theoretical — it is evidenced, published and in routine practice at SLHD. 

The enabling technology must be clinically governed and deeply integrated — not just a consumer app, but a platform connecting monitoring, medical records, escalation logic and clinical teams. 

Patient experience in well-designed virtual models can be significantly better than inpatient care — with implications for quality metrics, regulatory performance and reputational standing. 

The iCAD model is applicable beyond diverticulitis — the infrastructure supports a broad range of acute and sub-acute conditions managed through virtual ward and Hospital at Home programmes. 

The question for health system leaders is not whether to invest in virtual care. It is what it takes to do it safely, at scale, for the full breadth of conditions that could benefit. 

About Miya Precision 

Miya Precision is Alcidion’s flagship product: an Intelligent Care Platform that consolidates real-time data from across the care ecosystem into a single longitudinal record. The platform gives clinicians and leaders the actionable intelligence they need to reduce bottlenecks, release capacity and deliver safer, more coordinated patient journeys, deployed across major health systems in Australia, the United Kingdom and New Zealand.  

In the iCAD trial, Miya Precision provided the clinical infrastructure underpinning the virtual hospital model — integrating wearable device data, the patient-facing Miya Care app, and the hospital EMR into a real-time clinical dashboard with embedded escalation logic and workflow management. 

If you are exploring virtual ward or Hospital at Home models and want to understand how Miya Precision supports them, we would welcome the conversation. 

---

Reference 

_{Yang PF, Hay P, Hutchings OR, et al. Virtual Care of Acute Diverticulitis: A Phase I/II Randomised Clinical Feasibility Trial. ANZ Journal of Surgery. 2026. doi: 10.1111/ans.70826} 

_{Sussex ICS, 2025: Sussex achieves top national ranking for admission avoidance virtual wards. Accessed via https://www.sussex.ics.nhs.uk/sussex-achieves-top-national-ranking-for-admission-avoidance-virtual-wards/}